Please login to the form below

Not currently logged in
Email:
Password:

FDA approves 14 generic copies of GSK's Coreg

The FDA allows 14 generic manufacturers to sell first generic versions of GlaxoSmithKline's blood pressure drug Coreg in the US

The FDA has given 14 generic manufacturers permission to sell the first generic versions of GlaxoSmithKline's (GSK) blood pressure drug Coreg (carvedilol) on the US market.

The agency stated on 5 September 2007 that the companies, which included Caraco Pharmaceutical, Mylan, Ranbaxy and Watson, could sell generic versions of Coreg in strengths of 3.125 mg, 6.25 mg, 12.5 mg and 25 mg.

Coregis is approved in the US to treat high blood pressure, mild-to-severe chronic heart failure and left ventricular dysfunction following a heart attack.

GSK sells a newer, daily reformulation of the drug called Coreg CR, which is patent protected until 2023, according to the UK-based firm.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics